INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Iannone Robert sold JAZZ

EVP, Global Head of R&D & CMO · Jazz Pharmaceuticals plc · Ordinary Shares

Side
SELL
Value
$2.33M
Shares
9,259
Price
$251.95
Executed
Aug 27, 2026
Disclosed
Aug 31, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Aug 27 executedAug 31, 2026 disclosed

JAZZ · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
23/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+14 / 25

    $2.3M reported value · 12.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · JAZZ

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    GD
    Gala Renee DDirector, President & CEO
    JAZZJazz Pharmaceuticals plc
    Open-market sale · 10b5-1 plan
    		SELL$473K
    2,000 sh
    		Oct 6, 2026Oct 7, 2026
    traded Oct 6, 2026
    		+1dSEC FORM 4

    Evidence

    16
    PM
    Patil Neena MEVP & Chief Legal Officer
    JAZZJazz Pharmaceuticals plc
    Open-market sale · 10b5-1 plan
    		SELL$289K
    1,200 sh
    		Sep 10, 2026Sep 14, 2026
    traded Sep 10, 2026
    		+4dSEC FORM 4

    Evidence

    5
    HE
    Henderson Mary ElizabethSVP, Technical Operations
    JAZZJazz Pharmaceuticals plc
    Tax withholding
    		F$3,618
    15 sh
    		Sep 8, 2026Sep 10, 2026
    traded Sep 8, 2026
    		+2dSEC FORM 4

    Evidence

    15
    HE
    Henderson Mary ElizabethSVP, Technical Operations
    JAZZJazz Pharmaceuticals plc
    Tax withholding
    		F$343K
    1,412 sh
    		Sep 8, 2026Sep 10, 2026
    traded Sep 8, 2026
    		+2dSEC FORM 4

    Evidence

    15
    HE
    Henderson Mary ElizabethSVP, Technical Operations
    JAZZJazz Pharmaceuticals plc
    Tax withholding
    		F$501K
    2,076 sh
    		Aug 31, 2026Sep 2, 2026
    traded Aug 31, 2026
    		+2dSEC FORM 4

    Evidence

    23
    KP
    Kennedy PatrickDirector
    JAZZJazz Pharmaceuticals plc
    Tax withholding
    		F$444K
    1,840 sh
    		Aug 31, 2026Sep 2, 2026
    traded Aug 31, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KP
    Kennedy PatrickDirector
    JAZZJazz Pharmaceuticals plc
    Tax withholding
    		F$3,661
    15 sh
    		Aug 31, 2026Sep 2, 2026
    traded Aug 31, 2026
    		+2dSEC FORM 4

    Evidence

    5
    HE
    Henderson Mary ElizabethSVP, Technical Operations
    JAZZJazz Pharmaceuticals plc
    Tax withholding
    		F$3,914
    16 sh
    		Aug 31, 2026Sep 2, 2026
    traded Aug 31, 2026
    		+2dSEC FORM 4

    Evidence

    23
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Open-market sale · 10b5-1 plan
    		SELL$2.84M
    11.4K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    23
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Open-market sale · 10b5-1 plan
    		SELL$4.51M
    18.2K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    5
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Option exercise · 10b5-1 plan
    		M$400K
    2,916 sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    16
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Option exercise · 10b5-1 plan
    		M$3.78M
    27.6K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    16
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Option exercise · 10b5-1 plan
    		M$2.95M
    26.1K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    0
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Option exercise · 10b5-1 plan
    		M—
    27.6K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    0
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Option exercise · 10b5-1 plan
    		M—
    26.1K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    0
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Option exercise · 10b5-1 plan
    		M—
    2,916 sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    0
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Option exercise · 10b5-1 plan
    		M—
    884 sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    13
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Open-market sale · 10b5-1 plan
    		SELL$76K
    300 sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    27
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Open-market sale · 10b5-1 plan
    		SELL$4.92M
    19.6K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    23
    IR
    Iannone RobertEVP, Global Head of R&D & CMO
    JAZZJazz Pharmaceuticals plc
    Open-market sale · 10b5-1 plan
    		SELL$4.53M
    18.1K sh
    		Aug 27, 2026Aug 31, 2026
    traded Aug 27, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001737329-26-000016
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 27, 2026
    Published
    Aug 31, 2026
    Ingested by INSIDER
    Nov 5, 02:19 UTC
    Last re-read
    Nov 5, 02:19 UTC

    Extracted facts

    Filer
    Iannone Robert
    Role
    EVP, Global Head of R&D & CMO
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Jazz Pharmaceuticals plc
    Ticker
    JAZZ
    Shares
    9,259
    Price per share
    $251.95
    Value
    $2,332,804
    Execution date (reported)
    Aug 27, 2026
    Owned after transaction
    66.0K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 9,259
    • Price: $251.9499

    = $2,332,804

    What this establishes

    Iannone Robert filed this Form 4 reporting a open-market sale of JAZZ on Aug 27, 2026. It became public on Aug 31, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, Global Head of R&D & CMO
    Iannone Robertcik:0001737329
    Issuer
    Jazz Pharmaceuticals plccik:0001232524

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.